Psychotomimesis Mediated by κ Opiate Receptors
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The κ opioid agonists are analgesics that seem to be free of undesired morphine-like effects. Their dysphoric actions observed with the κ agonist cyclazocine are thought to be mediated by an action at σ-phencyclidine receptors. The benzomorphan κ agonist MR 2033 is inactive at σ-phencyclidine receptors. In male subjects, the opiate-active (-)-isomer, but not the (+)-isomer, elicited dose-dependent dysphoric and psychotomimetic effects that were antagonized by naloxone. Thus, κ opiate receptors seem to mediate psychotomimetic effects. In view of the euphorigenic properties of μ agonists, our results imply the existence of opposed opioid systems affecting emotional and perceptual experiences.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“agonism of κ-opioid receptors were shown to produce depression-like symptoms in humans (Pfeiffer et al., 1986).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Pfeiffer et al., 1986
In the citing paper
“Nonetheless, the three receptor types have different behavioral domains, with MOR and DOR mediating generally positive motivation and affect, while KOR mediates generally negative motivation and aversion (Pfeiffer et al 1986; Shippenberg et al 1987; Pecina and Berridge 2000; McLaughlin et al 2003; for reviews see Van Ree et al 2000; Le Merrer et al 2009).”
From The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction (2012) · cites this paper as Pfeiffer et al 1986
In the citing paper
“Kappa receptor agonists induce anxiogenic and dysphoric effects in humans (141-143) and depressive-like behavior in animals (i.e., increased immobility in the forced swim test) (144, 145).”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [141]
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E., & Gilbert, P. E. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30536-7 · Cited by 2,992
Pharmacologic effects of CI‐581, a new dissociative anesthetic, in man
Domino, E. F., Chodoff, P., & Corssen, G. (1965) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196563279 · Cited by 748
Martin, W. R. (1983) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06637-2 · Cited by 648
Thrills in response to music and other stimuli
Goldstein, A. (1980) · Physiological Psychology · doi:10.3758/bf03326460 · Cited by 522
Mucha, R. F., & Herz, A. (1985) · Psychopharmacology · doi:10.1007/bf00432213 · Cited by 510
Self-citationThe binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties
Magnan, J., Paterson, S. J., Tavani, A., & Kosterlitz, H. W. (1982) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00495865 · Cited by 509
A CLASSIFICATION OF OPIATE RECEPTORS THAT MEDIATE ANTINOCICEPTION IN ANIMALS
TYERS, M. B. (1980) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1980.tb07041.x · Cited by 341
Opiate receptor binding sites in human brain
Pfeiffer, A., Pasi, A., Mehraein, P., & Herz, A. (1982) · Brain Research · doi:10.1016/0006-8993(82)91150-7 · Cited by 298
Self-citationPhencyclidine (angel dust)/sigma "opiate" receptor: visualization by tritium-sensitive film.
Quirion, R., Hammer, R. P., Herkenham, M., & Pert, C. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5881 · Cited by 254
Research works printed but not linked: 6
- Jasinski, D. R., Drug Addiction 1: 216 (1977).
- MARTIN, W.R., PHARMACOL REV 35: 283 (1984).
- MARTIN, W.R., SUBSTANCE AND ALCOHOL ACTIONS/MISUSE 1: 269 (1980).
- Shearman, G. T., Drug Discrimination: Application in CNS Pharmacology: 37 (1982).
- VAUPEL, D.B., FAILURE OF NALTREXONE (NTX) TO ANTAGONIZE PHENCYCLIDINE (PCP) AND THE OPIOID SKF-10047 (SKF) IN THE DOG, FEDERATION PROCEEDINGS 41: 1333 (1982).
- Zerssen, D. V., Assessment of Depression: 270 (1985).
Cited by
Items 101–200 of 956
Chartoff, E., Sawyer, A., Rachlin, A., Potter, D., Pliakas, A., & Carlezon, W. A. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.06.014 · Cited by 142
Opioid Receptors in Immune and Glial Cells—Implications for Pain Control
Machelska, H., & Celik, M. Ö. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00300 · Cited by 159
Carlezon, W. A., & Krystal, A. D. (2016) · Depression and Anxiety · doi:10.1002/da.22500 · Cited by 158
Neurobiology of dysregulated motivational systems in drug addiction
Edwards, S., & Koob, G. F. (2010) · Future Neurology · doi:10.2217/fnl.10.14 · Cited by 157
“Dynorphin has long been hypothesized to mediate negative emotional states, since k-receptor agonists produce place aversions [93], depression and dysphoria in humans [94].”
BackgroundSystemic Kappa Opioid Receptor Agonists in the Treatment of Chronic Pruritus: A Literature Review
Phan, N., Lotts, T., Antal, A., Bernhard, J., & Ständer, S. (2012) · Acta Dermato Venereologica · doi:10.2340/00015555-1353 · Cited by 147
Opioid reward mechanisms: a key role in drug abuse?
Herz, A. (1998) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-76-3-252 · Cited by 146
Self-citationIdentification of Novel Functionally Selective κ-Opioid Receptor Scaffolds
White, K. L., Scopton, A. P., Rives, M., Bikbulatov, R. V., Polepally, P. R., Brown, P. J., Kenakin, T., Javitch, J. A., Zjawiony, J. K., & Roth, B. L. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.089649 · Cited by 155
Development of pharmacotherapies for drug addiction: a Rosetta stone approach
Koob, G. F., Kenneth Lloyd, G., & Mason, B. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2828 · Cited by 154
Presynaptic Opioid and Nicotinic Receptor Modulation of Dopamine Overflow in the Nucleus Accumbens
Britt, J. P., & McGehee, D. S. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4275-07.2008 · Cited by 130
σ receptors: Putative links between nervous, endocrine and immune systems
Su, T. (1991) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1991.tb16226.x · Cited by 152
Heidbreder, C. A., Goldberg, S. R., & Shippenberg, T. S. (1993) · Brain Research · doi:10.1016/0006-8993(93)90228-f · Cited by 151
Sverrisdóttir, E., Lund, T. M., Olesen, A. E., Drewes, A. M., Christrup, L. L., & Kreilgaard, M. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.03.020 · Cited by 149
Use of Herpes Virus Amplicon Vectors to Study Brain Disorders
Neve, R. L., Neve, K. A., Nestler, E. J., & Carlezon, W. A. (2005) · BioTechniques · doi:10.2144/05393ps01 · Cited by 144
Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment
Crowley, N. A., & Kash, T. L. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.01.001 · Cited by 129
Berrocoso, E., Sanchez-Blazquez, P., Garzon, J., & Mico, J. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788168100 · Cited by 126
Effects of Kappa Opioid Agonists on Cocaine- and Food-Maintained Responding by Rhesus Monkeys
Mello, N. K., & Negus, S. S. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37657-8 · Cited by 140
Tejeda, H. A., Counotte, D. S., Oh, E. J., Ramamoorthy, S., Schultz‐Kuszak, K., Bäckman, C. M., Chefer, V., O’Donnell, P., & Shippenberg, T. S. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.76 · Cited by 143
Sex Differences in Kappa Opioid Receptor Function and Their Potential Impact on Addiction
Chartoff, E. H., & Mavrikaki, M. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00466 · Cited by 135
Allostery at opioid receptors: modulation with small molecule ligands
Livingston, K. E., & Traynor, J. R. (2018) · British Journal of Pharmacology · doi:10.1111/bph.13823 · Cited by 134
SHIPPENBERG, T. S., CHEFER, V. I., ZAPATA, A., & HEIDBREDER, C. A. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03558.x · Cited by 123
Recent Advances in the Biological Study of Personality Disorders
New, A. S., Goodman, M. S., Triebwasser, J., & Siever, L. J. (2008) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2008.03.011 · Cited by 138
Effects of kappa opioids in the inflamed rat colon
Sengupta, N. J., Snider, A., Su, X., & Gebhart, F. (1999) · Pain · doi:10.1016/s0304-3959(98)00175-4 · Cited by 138
The Nonmedical Use of Ketamlne, Part Two: A Review of Problent Use and Dependence
Jansen, K. L. R., & Darracot-Cankovic, R. (2001) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2001.10400480 · Cited by 137
Biased ligands at opioid receptors: Current status and future directions
Che, T., Dwivedi‐Agnihotri, H., Shukla, A. K., & Roth, B. L. (2021) · Science Signaling · doi:10.1126/scisignal.aav0320 · Cited by 136
Kappa opioids and the modulation of pain
Kivell, B. M., & Prisinzano, T. E. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1819-6 · Cited by 136
Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development
Aldrich, J. V., & McLaughlin, J. P. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9105-4 · Cited by 136
Borderline personality disorder: a dysregulation of the endogenous opioid system?
Bandelow, B., Schmahl, C., Falkai, P., & Wedekind, D. (2010) · Psychological Review · doi:10.1037/a0018095 · Cited by 135
Brand, B. L., Lanius, R., Vermetten, E., Loewenstein, R. J., & Spiegel, D. (2012) · Journal of Trauma & Dissociation · doi:10.1080/15299732.2011.620687 · Cited by 114
Reisine, T. (1995) · Neuropharmacology · doi:10.1016/0028-3908(95)00025-2 · Cited by 135
Nealey, K. A., Smith, A. W., Davis, S. M., Smith, D. G., & Walker, B. M. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.012 · Cited by 133
“…Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript KOR stimulation produces dysphoria, place aversions (Mucha and Herz 1985; Pfeiffer et al. 1986; Land et al. 2008) and a phenotype indicative of a depressive-like state (e.g., see Mague et al. 2003; Todtenkopf et al. 2004).”
BackgroundGABAergic MECHANISMS OF OPIATE REINFORCEMENT
Xi, Z.-X. (2002) · Alcohol and Alcoholism · doi:10.1093/alcalc/37.5.485 · Cited by 123
A pharmacological profile of the novel, peripherally‐selectivek‐opioid receptor agonist, EMD 61753
Barber, A., Bartoszyk, G. D., Bender, H. M., Gottschlich, R., Greiner, H. E., Harting, J., Mauler, F., Minck, K.-O., Murray, R. D., Simon, M., et al. (1994) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1994.tb17142.x · Cited by 133
Agonist-induced regulation and trafficking of $kappa; opioid receptors
Liu‐Chen, L. (2004) · Life Sciences · doi:10.1016/j.lfs.2003.10.041 · Cited by 132
The Nucleus Accumbens: A Common Target in the Comorbidity of Depression and Addiction
Xu, L., Nan, J., & Lan, Y. (2020) · Frontiers in Neural Circuits · doi:10.3389/fncir.2020.00037 · Cited by 115
Wee, S., Orio, L., Ghirmai, S., Cashman, J. R., & Koob, G. F. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1563-y · Cited by 121
Schindler, A. G., Messinger, D. I., Smith, J. S., Shankar, H., Gustin, R. M., Schattauer, S. S., Lemos, J. C., Chavkin, N. W., Hagan, C. E., Neumaier, J. F., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.3220-12.2012 · Cited by 118
Li, J.-G., Chen, C., & Liu-Chen, L.-Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200058200 · Cited by 117
Molecular and genetic substrates linking stress and addiction
Briand, L. A., & Blendy, J. A. (2010) · Brain Research · doi:10.1016/j.brainres.2009.11.002 · Cited by 125
“Activation of kappa opioid receptors is aversive; kappa agonists serve as negative reinforcers and produce dysphoria in humans and aversion in experimental animals (Mucha and Herz, 1985; Pfeiffer et al., 1986).”
BackgroundD3 Dopamine and Kappa Opioid Receptor Alterations in Human Brain of Cocaine‐overdose Victims
MASH, D. C., & STALEY, J. K. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb09286.x · Cited by 108
Buprenorphine–Naloxone Therapy in Pain Management
Chen, K. Y., Chen, L. L., & Mao, J. (2014) · Anesthesiology · doi:10.1097/aln.0000000000000170 · Cited by 124
An open-label study of a functional opioid κ antagonist in the treatment of opioid dependence
Rothman, R. B., Gorelick, D. A., Heishman, S. J., Eichmiller, P. R., Hill, B. H., Norbeck, J., & Liberto, J. G. (2000) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(99)00074-4 · Cited by 124
Kappa opioid receptors on dopaminergic neurons are necessary for kappa-mediated place aversion
Chefer, V. I., Bäckman, C. M., Gigante, E. D., & Shippenberg, T. S. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.171 · Cited by 122
Synthesis and κ-Opioid Receptor Activity of Furan-Substituted Salvinorin A Analogues
Riley, A. P., Groer, C. E., Young, D. A., Ewald, A. W. M., Kivell, B. M., & Prisinzano, T. E. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501521d · Cited by 122
Tejeda, H. A., & Bonci, A. (2018) · Brain Research · doi:10.1016/j.brainres.2018.09.023 · Cited by 122
A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
Mores, K. L., Cummins, B. R., Cassell, R. J., & van Rijn, R. M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00407 · Cited by 121
The kappa-opioid receptor: Evidence for the different subtypes
Wollemann, M., Benyhe, S., & Simon, J. (1993) · Life Sciences · doi:10.1016/0024-3205(93)90451-8 · Cited by 120
Schlosburg, J. E., Whitfield, T. W., Park, P. E., Crawford, E. F., George, O., Vendruscolo, L. F., & Koob, G. F. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1979-13.2013 · Cited by 119
Molecular mechanisms of maternal cannabis and cigarette use on human neurodevelopment
Morris, C. V., DiNieri, J. A., Szutorisz, H., & Hurd, Y. L. (2011) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07884.x · Cited by 111
Targeting Itch with Ligands Selective for κ Opioid Receptors
Cowan, A., Kehner, G. B., & Inan, S. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-44605-8_16 · Cited by 117
Molecular mechanism of biased signaling at the kappa opioid receptor
Daibani, A. E., Paggi, J. M., Kim, K., Laloudakis, Y. D., Popov, P. A., Bernhard, S. M., Krumm, B. E., Olsen, R. H. J., DiBerto, J. F., Carroll, F. I., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37041-7 · Cited by 117
Chemical brain anatomy in schizophrenia
Sedvall, G., & Farde, L. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91508-7 · Cited by 117
Neuroanatomical localization ofκ1and κ2 opioid receptors in rat and guinea pig brain
Unterwald, E. M., Knapp, C. M., & Zukin, R. S. (1991) · Brain Research · doi:10.1016/0006-8993(91)91186-5 · Cited by 117
Neural Substrates of Psychostimulant Withdrawal-Induced Anhedonia
D’Souza, M. S., & Markou, A. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_20 · Cited by 116
Hedonic homeostatic dysregulation as a driver of drug-seeking behavior
Koob, G. F. (2008) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2009.04.002 · Cited by 114
Wells, A. M., Ridener, E., Bourbonais, C. A., Kim, W., Pantazopoulos, H., Carroll, F. I., Kim, K.-S., Cohen, B. M., & Carlezon, W. A. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.0885-17.2017 · Cited by 108
Xi, Z.-X., Fuller, S. A., & Stein, E. A. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37186-1 · Cited by 109
Arendt‐Nielsen, L., Olesen, A. E., Staahl, C., Menzaghi, F., Kell, S. H., Wong, G. Y., & Drewes, A. M. (2009) · Anesthesiology · doi:10.1097/aln.0b013e3181af6356 · Cited by 113
An Allelic Variation in the Human Prodynorphin Gene Promoter Alters Stimulus‐Induced Expression
Zimprich, A., Kraus, J., Wöltje, M., Mayer, P., Rauch, E., & Höllt, V. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.740472.x · Cited by 104
Opioid hyperexcitability: the application of alternate opioid therapy
Macdonald, N., Der, L., Allan, S. J., & Champion, P. (1993) · Pain · doi:10.1016/0304-3959(93)90232-e · Cited by 113
Muschamp, J. W., Van't Veer, A., Parsegian, A., Gallo, M. S., Chen, M., Neve, R. L., Meloni, E. G., & Carlezon, W. A. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5973-10.2011 · Cited by 103
Smith, J. S., Schindler, A. G., Martinelli, E., Gustin, R. M., Bruchas, M. R., & Chavkin, C. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2980-11.2012 · Cited by 100
Endogenous opioid systems alterations in pain and opioid use disorder
Higginbotham, J. A., Markovic, T., Massaly, N., & Morón, J. A. (2022) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2022.1014768 · Cited by 111
Russell, S. E., Rachlin, A. B., Smith, K. L., Muschamp, J., Berry, L., Zhao, Z., & Chartoff, E. H. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.07.042 · Cited by 102
κ-Opioid Receptors within the Nucleus Accumbens Shell Mediate Pair Bond Maintenance
Resendez, S. L., Kuhnmuench, M., Krzywosinski, T., & Aragona, B. J. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5779-11.2012 · Cited by 110
“Here, we demonstrate that blockade of -opioid receptors (known to mediate aversion) (Mucha and Herz, 1985; Pfeiffer et al., 1986), but not -opioid receptors (known to mediate reward and positive hedonics) (Weeks, 1962; Bozarth and Wise, 1981), prevents selective aggression.”
BackgroundDynorphin–Still an Extraordinarily Potent Opioid Peptide
Chavkin, C. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.083337 · Cited by 110
Biomarkers of Epileptogenesis: Psychiatric Comorbidities (?)
Kanner, A. M., Mazarati, A. M., & Koepp, M. J. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0271-4 · Cited by 109
Paine, T. A., Tomasiewicz, H. C., Zhang, K., & Carlezon, W. A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.11.017 · Cited by 109
Ansonoff, M. A., Zhang, J., Czyzyk, T. A., Rothman, R. B., Stewart, J., Xu, H., Zjwiony, J., Siebert, D. J., Yang, F., Roth, B. L., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.101998 · Cited by 108
Butelman, E. R., Harris, T. J., & Kreek, M. J. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1638-0 · Cited by 108
Valiquette, M., Vu, H. K., Yue, S. Y., Wahlestedt, C., & Walker, P. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.31.18789 · Cited by 108
Differential messenger RNA expression of prodynorphin and proenkephalin in the human brain
Hurd, Y. L. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00002-4 · Cited by 107
Kapusta, D. R., Sezen, S. F., Chang, J., Lippton, H. L., & Kenigs, V. A. (1996) · Life Sciences · doi:10.1016/s0024-3205(96)00593-0 · Cited by 107
Liu, J. J., Chiu, Y.-T., DiMattio, K. M., Chen, C., Huang, P., Gentile, T. A., Muschamp, J. W., Cowan, A., Mann, M., & Liu‐Chen, L. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0155-0 · Cited by 106
Does the kappa opioid receptor system contribute to pain aversion?
Cahill, C. M., Taylor, A. M. W., Cook, C., Ong, E., Morón, J. A., & Evans, C. J. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00253 · Cited by 105
Opioid receptor random mutagenesis reveals a mechanism for G protein–coupled receptor activation
Décaillot, F. M., Befort, K., Filliol, D., Yue, S. Y., Walker, P., & Kieffer, B. L. (2003) · Nature Structural & Molecular Biology · doi:10.1038/nsb950 · Cited by 105
Li, J., Benovic, J., & Liu‐Chen, L. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23112-6 · Cited by 105
Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats
Nemeth, C. L., Paine, T. A., Rittiner, J. E., Béguin, C., Carroll, F. I., Roth, B. L., Cohen, B. M., & Carlezon, W. A. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1834-7 · Cited by 104
Modulation of drug-induced sensitization processes by endogenous opioid systems
Spanagel, R. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(94)00176-g · Cited by 104
Peripheral Effects of the κ-Opioid Agonist EMD 61753 on Pain and Inflammation in Rats and Humans
Machelska, H., Pflüger, M., Weber, W., Piranvisseh-Völk, M., Daubert, J. D., DeHaven, R. N., & Stein, C. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34907-9 · Cited by 104
σ Receptors: From Molecule to Man
Ferris, C. D., Hirsch, D. B., Brooks, B. P., & Snyder, S. H. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb08213.x · Cited by 104
Targeting opioid dysregulation in depression for the development of novel therapeutics
Browne, C. A., & Lucki, I. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.009 · Cited by 95
Kappa opioid agonists suppress chloroquine-induced scratching in mice
Inan, S., & Cowan, A. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.09.010 · Cited by 103
Valdez, G. R., Platt, D. M., Rowlett, J. K., Rüedi-Bettschen, D., & Spealman, R. D. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.125484 · Cited by 99
The role of κ-opioid receptor activation in mediating antinociception and addiction
Wang, Y., Sun, J.-F., Tao, Y., Chi, Z., & Liu, J. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.138 · Cited by 99
GEC1 Interacts with the κ Opioid Receptor and Enhances Expression of the Receptor
Chen, C., Li, J., Chen, Y., Huang, P., Wang, Y., & Liu‐Chen, L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m509805200 · Cited by 99
Conditioning of Opioid Reinforcement: Neuroanatomical and Neurochemical Substrates
Shippenberg, T. S., Herz, A., Spanagel, R., Bals-Kubik, R., & Stein, C. (1992) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1992.tb25980.x · Cited by 99
Self-citationStaley, J. K., Rothman, R. B., Rice, K. C., Partilla, J., & Mash, D. C. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-21-08225.1997 · Cited by 94
Zheng, M.-Q., Nabulsi, N., Kim, S. J., Tomasi, G., Lin, S.-F., Mitch, C., Quimby, S., Barth, V., Rash, K., Masters, J., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.109512 · Cited by 89
Dextromethorphan and sigma ligands: Common sites but diverse effects
Musacchio, J. M., Klein, M., & Canoll, P. (1989) · Life Sciences · doi:10.1016/0024-3205(89)90510-9 · Cited by 97
Pharmacokinetics of the plant-derived κ-opioid hallucinogen salvinorin A in nonhuman primates
Schmidt, M. D., Schmidt, M. S., Butelman, E. R., Harding, W. W., Tidgewell, K. J., Murry, D. J., Kreek, M. J., & Prisinzano, T. E. (2005) · Synapse · doi:10.1002/syn.20191 · Cited by 95
Schindler, A. G., Li, S., & Chavkin, C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.67 · Cited by 84
The Kappa-Opioid Agonist U69,593 Blocks Cocaine-Induced Enhancement of Brain Stimulation Reward
Tomasiewicz, H. C., Todtenkopf, M. S., Chartoff, E. H., Cohen, B. M., & Carlezon, W. A. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.029 · Cited by 90
Ligand and G-protein selectivity in the κ-opioid receptor
Han, J., Zhang, J., Nazarova, A. L., Bernhard, S. M., Krumm, B. E., Zhao, L., Lam, J. H., Rangari, V. A., Majumdar, S., Nichols, D. E., et al. (2023) · Nature · doi:10.1038/s41586-023-06030-7 · Cited by 91
Jackson, K. J., Carroll, F. I., Negus, S. S., & Damaj, M. I. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1803-1 · Cited by 86
Temporal upregulation of prodynorphin mRNA in the primate striatum after cocaine self‐administration
Fagergren, P., Smith, H. R., Daunais, J. B., Nader, M. A., Porrino, L. J., & Hurd, Y. L. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02636.x · Cited by 88
Dooley, C. T., Chung, N. N., Schiller, P. W., & Houghten, R. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.22.10811 · Cited by 90
Butelman, E. R., & Kreek, M. J. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00190 · Cited by 77
Desipramine Reduces Stress-Activated Dynorphin Expression and CREB Phosphorylation in NAc Tissue
Chartoff, E. H., Papadopoulou, M., MacDonald, M. L., Parsegian, A., Potter, D. N., Konradi, C. L., & Carlezon, W. A. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.051417 · Cited by 89
Dopamine and opioid systems interact within the nucleus accumbens to maintain monogamous pair bonds
Resendez, S. L., Keyes, P. C., Day, J. J., Hambro, C., Austin, C. J., Maina, F. K., Eidson, L. N., Porter-Stransky, K. A., Nevárez, N., McLean, J. W., et al. (2016) · eLife · doi:10.7554/elife.15325 · Cited by 88
“Given that activation of KORs is associated with aversive states (Mucha and Herz, 1985; Pfeiffer et al., 1986; Shippenberg and Herz, 1986; Bals-Kubik et al., 1989), we first determined if activation of NAc KORs prior to pairing with a novel social stimulus is sufficient to tag a…”
Genetic association studies of methamphetamine use disorders: A systematic review and synthesis
Bousman, C., Glatt, S. J., Everall, I., & Tsuang, M. T. (2009) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30936 · Cited by 88
Metadata
- Authors
- Pfeiffer, A., Brantl, V., Herz, A., & Emrich, H. M.
- Affiliations
- LMU Klinikum (DE)
- Boehringer Ingelheim (Germany) (DE)
- Max Planck Society (DE)
- Max Planck Institute of Psychiatry (DE)
- ORCID
- Pfeiffer, Andreas
- Venue
- Science
- Published
- 1986-08-15
- Volume
- 233
- Issue
- 4765
- Pages
- 774-776
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2032643119
- Cited by
- 857
- References
- 30
- Citations by year
- 2026: 20 · 2025: 19 · 2024: 23 · 2023: 17 · 2022: 18 · 2021: 38 · 2020: 42 · 2019: 21 · 2018: 27 · 2017: 24 · 2016: 37 · 2015: 38 · 2014: 30 · 2013: 35 · 2012: 41
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- psychotomimetic effects, kappa opioid receptor, kappa opioid receptor agonists, cyclazocine, naloxone antagonism, stereoisomers, mu-opioid receptor agonists, euphoria, analgesia
- MeSH terms
- Adult, Anxiety, Benzomorphans, Humans, Male, Middle Aged, Morphinans, Naloxone, Personality Tests, Phencyclidine, Receptors, Opioid, Receptors, Opioid, kappa
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.